fda compounded tirzepatide warning 2024 2025 September 2, 2025: U.S. compounding restrictions have stemmed a flood of semaglutide and – Partnership for Safe Medicines The FDA has issued warning
Description
Diabetes or weight loss: why the indication makes the difference Mounjaro is a special case, because tirzepatide stands behind two very different situations
Since theres currently no generic version available for tirzepatide, all prescriptions are brand-name only
Abstract The incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) mediate insulin responses that are proportionate to nutrient intake to facilitate glucose tolerance 1

Who Should Not Be Included in Research Protocols Using These Compounds Research exclusion criteria documented in clinical trials for both compounds include subjects with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastrointestinal disease [5][8]

However, more research is needed to confirm this effect and understand how it contributes to the overall weight loss observed in clinical trials

But for all its positives (of which there are a lot, BTW), the drug does come with some negatives, such as nausea